JP2024543983A5 - - Google Patents

Info

Publication number
JP2024543983A5
JP2024543983A5 JP2024532556A JP2024532556A JP2024543983A5 JP 2024543983 A5 JP2024543983 A5 JP 2024543983A5 JP 2024532556 A JP2024532556 A JP 2024532556A JP 2024532556 A JP2024532556 A JP 2024532556A JP 2024543983 A5 JP2024543983 A5 JP 2024543983A5
Authority
JP
Japan
Prior art keywords
alkyl
group
membered
hydrogen
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543983A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/083936 external-priority patent/WO2023099612A1/en
Publication of JP2024543983A publication Critical patent/JP2024543983A/ja
Publication of JP2024543983A5 publication Critical patent/JP2024543983A5/ja
Pending legal-status Critical Current

Links

JP2024532556A 2021-12-01 2022-11-30 がんの処置のための縮環2-アミノ-3-シアノチオフェン及び誘導体 Pending JP2024543983A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284778P 2021-12-01 2021-12-01
US63/284,778 2021-12-01
PCT/EP2022/083936 WO2023099612A1 (en) 2021-12-01 2022-11-30 Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024543983A JP2024543983A (ja) 2024-11-26
JP2024543983A5 true JP2024543983A5 (cg-RX-API-DMAC7.html) 2025-11-28

Family

ID=84536000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532556A Pending JP2024543983A (ja) 2021-12-01 2022-11-30 がんの処置のための縮環2-アミノ-3-シアノチオフェン及び誘導体

Country Status (6)

Country Link
US (1) US20250296940A1 (cg-RX-API-DMAC7.html)
EP (1) EP4441053A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543983A (cg-RX-API-DMAC7.html)
CN (2) CN118647620A (cg-RX-API-DMAC7.html)
TW (1) TW202340209A (cg-RX-API-DMAC7.html)
WO (1) WO2023099612A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
CN116034106B (zh) 2020-06-02 2025-11-04 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CR20240233A (es) 2021-12-01 2024-07-17 Univ Vanderbilt Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
US20250019385A1 (en) * 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2024255795A1 (en) * 2023-06-14 2024-12-19 Insilico Medicine Ip Limited Kras inhibitors and uses thereof
WO2025016899A1 (en) 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
WO2025026903A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Imidazo pyrimidine compounds for the treatment of cancer
TW202510846A (zh) 2023-08-02 2025-03-16 美商耐瑞歐醫療公司 蛋白質酪胺酸磷酸酶降解劑及其用途
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
IL330174A (en) 2023-12-20 2026-08-01 Boehringer Ingelheim Int Gmbh Combination cancer treatment using zongratinib and KRAS G12C inhibitor
CN117946135A (zh) * 2024-01-24 2024-04-30 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025190158A1 (zh) * 2024-03-14 2025-09-18 四川科伦博泰生物医药股份有限公司 螺环化合物、其制备方法及用途
WO2025190342A1 (zh) * 2024-03-15 2025-09-18 苏州浦合医药科技有限公司 螺环化合物作为kras突变体抑制剂
WO2025201480A1 (zh) * 2024-03-28 2025-10-02 苏州浦合医药科技有限公司 螺环化合物作为kras突变体抑制剂
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202606711A (zh) * 2024-06-19 2026-02-16 香港商英矽智能科技知識產權有限公司 作為kras抑制劑的新化合物及其用途
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026007740A1 (zh) * 2024-07-04 2026-01-08 四川科伦博泰生物医药股份有限公司 螺环化合物、其制备方法及用途
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
TW202610653A (zh) * 2024-07-12 2026-03-16 美商榮山醫藥股份有限公司 用於治療疾病之螺環kras抑制劑
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026114957A1 (en) 2024-11-27 2026-06-04 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras degraders for the treatment of cancer
US20260146050A1 (en) 2024-11-27 2026-05-28 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors
CN119751476B (zh) * 2025-03-05 2025-06-03 苏州共康医药科技有限公司 螺环类化合物及其在医药上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
BR112021001709A2 (pt) * 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CR20220258A (es) * 2019-12-11 2022-07-03 Lilly Co Eli Inhibidores de kras g12c
TWI894229B (zh) 2020-03-16 2025-08-21 瑞士商諾華公司 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物
CN116034106B (zh) 2020-06-02 2025-11-04 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物

Similar Documents

Publication Publication Date Title
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2009535307A5 (cg-RX-API-DMAC7.html)
JP2023527891A5 (cg-RX-API-DMAC7.html)
JP2019512485A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2019517487A5 (cg-RX-API-DMAC7.html)
CA2897004C (en) (hetero) arylacetamide derivatives as antiretroviral agents
AU2015231226B2 (en) Antifungal compound process
US11040034B2 (en) Metalloenzyme inhibitor compounds
JP2022505841A5 (cg-RX-API-DMAC7.html)
JP2014530900A5 (cg-RX-API-DMAC7.html)
JP2019532928A5 (cg-RX-API-DMAC7.html)
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2006507326A5 (cg-RX-API-DMAC7.html)
JP2017523972A5 (cg-RX-API-DMAC7.html)
JP2022505597A5 (cg-RX-API-DMAC7.html)
JP2013544276A5 (cg-RX-API-DMAC7.html)
JP2018529690A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
RU2008107733A (ru) Ингибиторы gsk-3
JP2019527724A5 (cg-RX-API-DMAC7.html)
JP2018527354A5 (cg-RX-API-DMAC7.html)
JP2024507414A5 (cg-RX-API-DMAC7.html)
CN115697992A (zh) 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用
JP2011526286A5 (cg-RX-API-DMAC7.html)